Articles
The US Food and Drug Administration (FDA) today approved Genvoya as a complete regimen for the treatment of human immunodeficiency virus (HIV)-1 infection in adults and pediatric patients aged ≥12 years. Read More ›
By Chase Doyle
Two pilot programs aimed at reducing the utilization of inappropriate testosterone replacement therapy, particularly in the treatment of men with age-related hypogonadism, have shown success in raising awareness of evidence and safety concerns. Read More ›
The Cancer Clinical Trials Office (CCTO) at Stanford University, Palo Alto, CA, oversees a large clinical trials program. It provides regulatory, financial, research, and educational services for investigators conducting clinical trials. Read More ›
Today the US Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Read More ›
The US Food and Drug Administration (FDA) today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. Read More ›
The US Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. Read More ›
Today the US Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Read More ›
The US Food and Drug Administration (FDA) today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. Read More ›
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS)—liposarcoma and leiomyosarcoma—that cannot be removed by surgery (unresectable) or is advanced (metastatic). Read More ›
There are numerous complications that may develop in patients with cancer; some are related to the disease itself, whereas others are associated with agents or combination regimens used during the course of treatment. Read More ›